Literature DB >> 945997

Booster vaccination with further live attenuated measles vaccine.

J W Bass, S B Halstead, G W Fischer, J K Podgore, W R Pearl, M Schydlower, R A Wiebe, F M Ching.   

Abstract

Revaccination with live attenuated measles vaccine was evaluated in a large group of children to determine (1) if protective antibody to measles infection could be augmented and (2) after what interval will the revaccination yield optimal results. The rate of decline in measles hemagglutination-inhibition (HI) antibody was observed to be directly related to the time interval since the previous vaccination, and individuals with declining titers became increasingly responsive to revaccination with a maximal response approximately four to six years after previous vaccination. Six-month follow-up studies demonstrated sustained elevations in measles HI antibody titers. Measles-neutralizing antibody showed less tendency to sustain a titer increase with revaccination. The observations suggest that revaccination with live, further attenuated measles vaccine is safe and may augment immunity.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 945997

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  10 in total

1.  Measles immunity in the first year after birth and the optimum age for vaccination in Kenyan children. Collaborative study by the Ministry of Health of Kenya and the World Health Organization.

Authors: 
Journal:  Bull World Health Organ       Date:  1977       Impact factor: 9.408

2.  Measles antibody levels in children of rural and urban areas of Nigeria following vaccination campaign.

Authors:  N O Eghafona; L E Odama; S O Emejuaiwe; E N Obineche; D S Tafida
Journal:  Epidemiol Infect       Date:  1987-08       Impact factor: 2.451

Review 3.  Measles virus and its associated diseases.

Authors:  E M Morgan; F Rapp
Journal:  Bacteriol Rev       Date:  1977-09

4.  Inadequate immunity to measles in children vaccinated at an early age: effect of revaccination.

Authors:  F L Black; L L Berman; M Libel; C A Reichelt; F D Pinheiro; A Travassos da Rosa; F Figueira; E Siqueira Gonzales
Journal:  Bull World Health Organ       Date:  1984       Impact factor: 9.408

Review 5.  A research framework for evaluating the promotion of mental health and prevention of mental illness.

Authors:  L Eisenberg
Journal:  Public Health Rep       Date:  1981 Jan-Feb       Impact factor: 2.792

6.  More myths in international health planning.

Authors:  R England
Journal:  Am J Public Health       Date:  1978-02       Impact factor: 9.308

7.  Measles in a partially immunized community.

Authors:  L Wintermeyer; M G Myers
Journal:  Am J Public Health       Date:  1979-09       Impact factor: 9.308

8.  Comparative analysis of titers of antibody against measles virus in sera of vaccinated and naturally infected Japanese individuals of different age groups.

Authors:  Masae Itoh; Yoshinobu Okuno; Hak Hotta
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

9.  Duration of immunity following immunization with live measles vaccine: 15 years of observation in Zhejiang Province, China.

Authors:  B Dai; Z H Chen; Q C Liu; T Wu; C Y Guo; X Z Wang; H H Fang; Y Z Xiang
Journal:  Bull World Health Organ       Date:  1991       Impact factor: 9.408

10.  Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity.

Authors:  Kuan Rong Chan; Xiaohui Wang; Wilfried A A Saron; Esther Shuyi Gan; Hwee Cheng Tan; Darren Z L Mok; Summer Li-Xin Zhang; Yie Hou Lee; Cui Liang; Limin Wijaya; Sujoy Ghosh; Yin Bun Cheung; Steven R Tannenbaum; Soman N Abraham; Ashley L St John; Jenny G H Low; Eng Eong Ooi
Journal:  Nat Microbiol       Date:  2016-09-19       Impact factor: 17.745

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.